Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost bought 7,200 shares of the business’s stock in a transaction on Tuesday, October 11th. The shares were acquired at an average cost of $9.78 per share, for a total transaction of $70,416.00. Following the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $30,014,340.78. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, October 10th, Phillip Md Et Al Frost acquired 24,800 shares of Opko Health stock. The stock was purchased at an average cost of $9.82 per share, for a total transaction of $243,536.00.
  • On Thursday, October 6th, Phillip Md Et Al Frost acquired 4,200 shares of Opko Health stock. The stock was purchased at an average cost of $10.53 per share, for a total transaction of $44,226.00.
  • On Tuesday, October 4th, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. The stock was purchased at an average cost of $10.57 per share, for a total transaction of $38,052.00.
  • On Friday, September 30th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The stock was purchased at an average cost of $10.54 per share, for a total transaction of $18,972.00.
  • On Thursday, September 29th, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. The stock was purchased at an average cost of $10.67 per share, for a total transaction of $38,412.00.
  • On Wednesday, September 28th, Phillip Md Et Al Frost acquired 5,400 shares of Opko Health stock. The stock was purchased at an average cost of $11.01 per share, for a total transaction of $59,454.00.
  • On Tuesday, September 27th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The stock was purchased at an average cost of $11.16 per share, for a total transaction of $20,088.00.
  • On Monday, September 26th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The stock was purchased at an average cost of $11.04 per share, for a total transaction of $19,872.00.
  • On Friday, September 23rd, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The stock was purchased at an average cost of $10.95 per share, for a total transaction of $19,710.00.
  • On Thursday, September 22nd, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The stock was purchased at an average cost of $10.63 per share, for a total transaction of $19,134.00.

Shares of Opko Health Inc. (NYSE:OPK) traded down 1.04% during mid-day trading on Wednesday, reaching $9.56. 2,490,076 shares of the company’s stock traded hands. Opko Health Inc. has a one year low of $7.12 and a one year high of $11.85. The firm has a market cap of $5.26 billion and a price-to-earnings ratio of 40.00. The firm’s 50-day moving average is $10.06 and its 200 day moving average is $10.08.

Opko Health (NYSE:OPK) last posted its quarterly earnings data on Monday, August 8th. The company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. The firm earned $357.10 million during the quarter, compared to analysts’ expectations of $324.11 million. During the same quarter last year, the business earned ($0.09) earnings per share. The business’s quarterly revenue was up 742.2% on a year-over-year basis. Analysts predict that Opko Health Inc. will post ($0.05) earnings per share for the current year.

Insider Buying and Selling by Quarter for Opko Health (NYSE:OPK)

A number of institutional investors have recently bought and sold shares of OPK. ProShare Advisors LLC purchased a new position in Opko Health during the second quarter worth $100,000. Financial Architects Inc raised its position in Opko Health by 21.5% in the second quarter. Financial Architects Inc now owns 10,950 shares of the company’s stock worth $102,000 after buying an additional 1,940 shares during the period. First Citizens Bank & Trust Co. purchased a new position in Opko Health during the second quarter worth $103,000. Williams Jones & Associates LLC raised its position in Opko Health by 352.0% in the second quarter. Williams Jones & Associates LLC now owns 11,300 shares of the company’s stock worth $106,000 after buying an additional 8,800 shares during the period. Finally, Nuveen Fund Advisors LLC purchased a new position in Opko Health during the second quarter worth $131,000.

OPK has been the topic of a number of analyst reports. Jefferies Group reaffirmed a “hold” rating on shares of Opko Health in a research report on Wednesday, August 17th. JPMorgan Chase & Co. set a $14.00 target price on shares of Opko Health and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Deutsche Bank AG dropped their target price on shares of Opko Health from $11.00 to $10.00 and set a “hold” rating on the stock in a research report on Thursday, June 16th. Oppenheimer Holdings Inc. reissued an “outperform” rating on shares of Opko Health in a research report on Saturday, June 25th. Finally, Standpoint Research boosted their target price on shares of Opko Health from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, June 21st. Five equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Opko Health has a consensus rating of “Buy” and a consensus price target of $13.20.

Opko Health Company Profile

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.